Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Powerful Medical
9. November 2023
3 min to read

Poor Prognosis of Total Culprit Artery Occlusion in Patients Presenting with NSTEMI 

Overview:

Traditional ECG criteria miss nearly one-third of heart attack patients with a fully occluded artery, mislabeling them as “NSTEMI” despite needing urgent care. This retrospective study of 10,000 patients found they face longer treatment delays and nearly double the one-year mortality of “acute” STEMI patients, highlighting the need for better ECG-based risk stratification and faster intervention.

Published In: European Heart Journal
Presented Date: November 9, 2023

Background

The prognosis of STEMI and NSTEMI patients stratified according to invasive angiographic findings of an occluded culprit coronary, i.e., occlusion myocardial infarction (OMI), remains unclear.

This retrospective single-center study aimed to compare the clinical presentation, management, and all-cause mortality of STEMI, NSTEMI-OMI, and NSTEMI-Non-OMI (NSTEMI-NOMI).

Methods

Demographics, clinical and procedural data were pooled for all patients with an index ACS event between January 2011 and May 2021. Patients were classified according to the presence of OMI determined by angiography and troponin. All-cause mortality was compared by Kaplan Meier analysis at 1-year and landmark analysis up to 5 years after the ACS event.

Results

A total of 9,943 patients [64.1 ± 14.2 years, 62.2% males] were included and classified into STEMI (n=507), NSTEMI-OMI (n=685), NSTEMI-NOMI (n=1,535) and MI ruled-out (n=7,216). Median time to coronary angiography (CAG) was 1.4 hours for STEMI compared to 16.3 and 45.8 hours for NSTEMI-OMI and NSTEMI-NOMI, respectively (p<0.001) [Figure 1].

At one year, all-cause mortality occurred in 9.9% of STEMI patients vs. 18.1% of NSTEMI-OMI patients (hazard ratio, 1.84; 95% CI, 1.32 to 2.55; p<0.001) and 7.9% of NSTEMI-NOMI patients (hazard ratio, 0.79; 95% CI, 0.56 to 1.09; p=0.150) [Figure 2]. An unfavorable mortality outcome for NSTEMI-OMI compared to STEMI was maintained in the age and gender-adjusted analyses and landmark analysis beyond 1-year (hazard ratio, 2.59; 95% CI, 1.75 to 3.82; p<0.001).

Conclusion

Despite similar baseline demographics and angiographic findings, patients with NSTEMI-OMI have increased delays to reperfusion and unfavorable short and long-term all-cause mortality compared to STEMI. These findings support the need for more accurate and timely identification of NSTEMI-OMI.



Authors: R Herman, S W Smith, H P Meyers, D T Bertolone, A Leone, K Bermpeis, M Viscusi, M Martonak, J Bahyl, A Demolder, L Perl, W Wojakowski, J Bartunek, E Barbato

Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

Can an AI ECG algorithm improve diagnostic accuracy for acute coronary occlusion in the difficult subset of canceled catheterization lab activations?

Discordance in ECG interpretation between Emergency Medicine and Cardiology teams is common, and within canceled STEMI activations, a true acute coronary occlusion myocardial infarction (OMI) can go unrecognized. This retrospective study examined whether an AI ECG algorithm (Queen of Hearts™) could improve OMI detection in this difficult subset. Across three referral centers, the investigators analyzed 185 activations canceled for not meeting STEMI criteria, of which 17 met the definition of a missed OMI. The AI algorithm identified 16 of 17 cases, far exceeding STEMI criteria in sensitivity (94.1% vs. 47.1%), supporting its use as an adjunct to clinical judgment in ambiguous cases.

Artificial Intelligence-Assisted, ECG-Based Triage of Patients With Chest Pain to Immediate Invasive Treatment

Rapid identification of acute coronary occlusion (ACO) is critical in chest pain patients, yet conventional STEMI criteria miss occlusion in many NSTEMI cases, delaying life-saving invasive treatment. This retrospective study tested whether a deep learning ECG AI model could improve ACO detection in an unselected cohort of more than 4,000 consecutive patients from a German chest pain unit. Each 12-lead ECG was assessed using both standard STEMI criteria and the AI model, with ACO independently adjudicated by a blinded physician. The AI model clearly outperformed STEMI criteria, identifying 73 of 104 ACO cases versus 30 (area under the curve 0.958 vs. 0.589), with fewer false positives. The findings suggest AI-assisted ECG interpretation can detect subtle ischemic changes beyond established criteria and support faster triage of NSTE-ACO patients to immediate invasive care.

Join over 100,000 healthcare professionals who are already taking advantage of AI